1 Haschke M, Liechti ME. Nutzen und Risiken von Metamizol im Vergleich zu Paracetamol und NSAR. Swiss Med Forum. 2017;17(48):1067–73.
2 Stammschulte T, Ludwig WD, Muhlbauer B, Bronder E, Gundert-Remy U. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012.
Eur J Clin Pharmacol. 2015;71:1129–38.
3 Blaser LS, Tramonti A, Egger P, Haschke M, Krahenbuhl S, Ratz Bravo AE. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports.
Eur J Clin Pharmacol. 2015;71:209–17.
4 Brodner G, Gogarten W, Van Haken H, et al. Efficacy of intravenous paracetamol compared to dipyrone and parecoxib for postoperative pain management after minor-to-intermediate surgery: a randomised, double-blind trial. Eur J Anaesthesiol. 2011;28:125–32.
5 Theiler R. Ist Metamizol das «neue» Antirheumatikum? Swiss Med Forum. 2017;17(48):1061–2.
6 Hearn L, Derry S, Moore RA. Single dose dipyrone (metamizole) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2016;4:CD011421.
7 Schmitz A, Rossmann L, Kienbaum P, Pavlakovic G, Werdehausen R, Hohlfeld T. Dipyrone (metamizole) markedly interferes with platelet inhibition by aspirin in patients with acute and chronic pain. A case-control study. Eur J Anesthesiol. 2017;34:288–96.
8 Patrono C, Baigent C. Coxibs, traditional NSAIDs, and cardiovascular safety post-PRECISION: what we thought we knew then and what we think we know now. Clin Pharmacol Ther. 2017;102:238–45.